#what are pharmerging markets

[avinashdell]

Pharmerging Market is Projected To Witness Extensive Growth by 2025

The global pharmerging market is expected to reach USD 2,231.9 billion by 2025, according to a new report by Grand View Research, Inc. This market is expected to grow due to increasing geriatric population, increasing disease burden of chronic disorders and increasing healthcare expenditure.

According to the United Nations (UN), the number of people above the age of 60 years are estimated to be 901 million in 2015. This number is expected to increase to 1.4 billion by 2030 and 2.1 billion by 2050. The increasing geriatric population boosts the demand for better treatment options for chronic diseases such as hyperlipidemia, hypertension, cancer, dementia, congestive heart failure. According to a study conducted by Deloitte in 2011, the geriatric population accounts for almost 23.0-40.0% of the prescription drug market, and 40.0-50.0% of the OTC drug market.

Another driving factor for the pharmerging market is increasing healthcare expenditure. The global healthcare spending is expected to increase from USD 7.83 trillion in 2013 to USD 18.28 trillion in 2040. It has also been estimated that there will an increase of 3.4%, 3.0%, 2.4% in healthcare expenditure in upper middle-level income countries, lower middle-level income countries and in low-income level countries respectively.

The increasing disease burden of chronic diseases in developing countries is boosting the growth in the market. According to the Global Health Observatory data, in 2015, 70.0% of the deaths were due to non-communicable diseases (NCD). The major NCDs are cardiovascular diseases (CVD) which caused 45.0% of all NCD deaths, cancer which caused 22.0% of all NCD deaths and chronic obstructive pulmonary disease (COPD) which causes 10.0% of all NCD deaths, and diabetes which caused 4.0% of all NCD deaths.

Request Free Sample PDF of the research at: https://www.grandviewresearch.com/industry-analysis/pharmerging-market/request/rs1

[marketresearchtrendsblog]

Pharmerging Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2030

The report on the global pharmerging market provides qualitative and quantitative analysis for the period from 2017 to 2025. The report predicts the global pharmerging market to grow with a CAGR of 11.3% over the forecast period from 2019-2025. The study on pharmerging market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2017 to 2025. The report on pharmerging market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global pharmerging market over the period of 2017 to 2025. Moreover, the report is a collective presentation of primary and secondary research findings.

Request to Fill The Form To get Sample Copy of This Report: https://www.sdki.jp/sample-request-104037

Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global pharmerging market over the period of 2017 to 2025. Further, IGR- Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider. Report Findings 1) Drivers • The growing occurrence of non-transmissible illnesses • An increase in the geriatric population, growing life expectancy 2) Restraints • High costs, socio-political issues in cross geography transactions, and IP protection issues 3) Opportunities • High focus on developing innovative drugs Research Methodology A) Primary Research Our primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached include 1. Key Opinion Leaders associated with Infinium Global Research 2. Internal and External subject matter experts 3. Professionals and participants from the industry Our primary research respondents typically include 1. Executives working with leading companies in the market under review 2. Product/brand/marketing managers 3. CXO level executives 4. Regional/zonal/ country managers 5. Vice President level executives. B) Secondary Research Secondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. At Infinium Global Research, each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources. The secondary sources of the data typically include 1. Company reports and publications 2. Government/institutional publications 3. Trade and associations journals 4. Databases such as WTO, OECD, World Bank, and among others. 5. Websites and publications by research agencies Segment Covered The global pharmerging market is segmented on the basis of product, indications, and distribution channel. The Global Pharmerging Market by Product • Pharmaceuticals o Branded Prescription Drugs o Generic Drugs • OTC Drugs The Global Pharmerging Market by Indications • Lifestyle Diseases • Cancer and Autoimmune Diseases • Others The Global Pharmerging Market by Distribution Channel • Hospitals • Clinics • E-commerce • Drug Stores Expenditure. Company Profiles The companies covered in the report include • Abbott Laboratories • Koninklijke Philips N.V. • Merck & Co., Inc. • Novartis AG • Johnson & Johnson • Teva Pharmaceutical Industries Ltd. • AstraZeneca plc • GlaxoSmithKline plc. • Sun Pharmaceutical Industries What does this report deliver? 1. Comprehensive analysis of the global as well as regional markets of the pharmerging market. 2. Complete coverage of all the segments in the pharmerging market to analyze the trends, developments in the global market and forecast of market size up to 2025. 3. Comprehensive analysis of the companies operating in the global pharmerging market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company. 4. IGR- Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.

The dynamic nature of business environment in the current global economy is raising the need amongst business professionals to update themselves with current situations in the market. To cater such needs, Shibuya Data Count provides market research reports to various business professionals across different industry verticals, such as healthcare & pharmaceutical, IT & telecom, chemicals and advanced materials, consumer goods & food, energy & power, manufacturing & construction, industrial automation & equipment and agriculture & allied activities amongst others.

For more information, please contact:

Hina Miyazu

Shibuya Data Count Email: sales@sdki.jp Tel: + 81 3 45720790

[maxihealth]

In 2023, the U.S. Will Still Be the #1 Prescription Drug Spender in the World, IQVIA Forecasts

Today, as Congress kicks off hearings about the cost of prescription drugs in the United States, IQVIA published its 2019 report on The Global Use of Medicine in 2019 and Outlook to 2023. The top-line of the research is the robust pharma market growth will be driven by two factors, and limited by two others: spending in the U.S. and emerging markets (coined “pharmerging” by IQVIA) will push up spending, while limiting factors on growth will be increasing generics and expiration of brand patents.

The U.S. will continue to be the number 1 prescription drug spender in the world to 2023, IQVIA forecasts, shown in the first chart where I clipped the top 20 to 10 top spenders. The U.S. will be followed by China, Japan, Germany, and Brazil in 2023.

For context and comparison, note that the U.S. has some 326 million citizens, and China nearly 1.4 billion. China will have spent just over one-fourth of what the U.S. paid for prescription drugs in 2018, with roughly four times the number of health citizens.

The rate of growth of Rx spending looks fairly flat from 2019 to 2023, the second bar chart illustrates, with net growth of spending just over 4% by 2021-2023.

This moderate growth rate is a moment in time, because IQVIA expects a pipeline of new and more expensive products to be launched as older brands continue to come off-patent — the moderating force on the price-driven growth of the new specialty drugs.

The second chart illustrates costs of drugs by type and launch year, showing that the median list price for oncology and orphan drugs (defined as medicines that treat fewer than 200,000 patients globally) could exceed $200,000 per year by 2023. Thus, while the costs of traditional drugs aren’t increasing far above the rate of inflation, the new-new therapies are much higher-priced.

See the dark blue dot in 2023 north of the other dots, representing the median costs for a non-oncology drug with orphan status priced around $300,000.

Other key trends to expect leading to 2023 will be:

The rise of patient advocacy roles in pharma companies

The growing adoption of artificial intelligence and machine learning by pharma companies to drive more efficient drug discovery

More philanthropic organizations targeting neglected tropical and public health diseases

The increased use of real-world evidence (RWE) and patient involvement in clinical trials using consumer-generated technology.

IQVIA rightly calls out digital therapeutics (DTx) in this year’s report, noting the growth of mobile apps and digital tools submitted to the FDA for clearance or approvals. The first FDA cleared DTx was reSET from Pear Therapeutics, cleared in November 2018. This is used for the treatment of substance use disorder and is the first of many conditions Pear is developing in the mode of software-as-medicine to complement the usual standard of care.

DTx companies have been striking partnerships with pharma companies to help them “surround the pill” with service. We can anticipate more of these collaborations going forward as pharmas look to add value beyond the pill, and innovators leverage peoples’ everyday relationships with and trust in consumer technologies.

The limiting factor here will be proving the evidence for DTx on a case-by-case basis. Thus far, the FDA has been welcoming to these concepts.

Health Populi’s Hot Points:  I introduced this post noting today is the first of what will be a long and deep look into prescription drug pricing in America. IQVIA recognizes that, “the (U.S.) Federal government has proposed a sweeping set of pricing reforms for government programs with varying levels of impact and probability of being enacted.” Furthermore, “the next five years likely pose a number of challenges to biopharmaceutical companies, with payer actions on prices looming.”

The last chart was published today in Bloomberg, observing that drug stocks were under-performing ahead of today’s first Congressional hearing on the topic of drug prices.

The Democratic-led House of Representatives may be blamed for this hazing, but in fact voters across political party have been interested in the Federal government taking more assertive and proactive action for prescription drug prices. Polls among voters for several years have found that this issue is a concern for majorities of Democrats, Independents, and Republicans.

In an America lacking consensus across the wide range of issues on voters’ minds, health care costs – and particularly Rx costs and prices – rank top of mind for voters and House Democrats.

Americans have come to learn the role they play in subsidizing the cost of drugs and their development for the world’s health citizens. Note my math on the China ratio of 1:4 dollars spent on prescription drugs versus the U.S., with over four times the number of people.

This topic will inevitably be part of ongoing political debates as we lead up to the 2020 Presidential election. The patient is the consumer is the payor of health care, including prescription drugs at the point of purchase.

The post In 2023, the U.S. Will Still Be the #1 Prescription Drug Spender in the World, IQVIA Forecasts appeared first on HealthPopuli.com.

In 2023, the U.S. Will Still Be the #1 Prescription Drug Spender in the World, IQVIA Forecasts posted first on https://carilloncitydental.blogspot.com

[realselfblog]

In 2023, the U.S. Will Still Be the #1 Prescription Drug Spender in the World, IQVIA Forecasts

Today, as Congress kicks off hearings about the cost of prescription drugs in the United States, IQVIA published its 2019 report on The Global Use of Medicine in 2019 and Outlook to 2023. The top-line of the research is the robust pharma market growth will be driven by two factors, and limited by two others: spending in the U.S. and emerging markets (coined “pharmerging” by IQVIA) will push up spending, while limiting factors on growth will be increasing generics and expiration of brand patents.

The U.S. will continue to be the number 1 prescription drug spender in the world to 2023, IQVIA forecasts, shown in the first chart where I clipped the top 20 to 10 top spenders. The U.S. will be followed by China, Japan, Germany, and Brazil in 2023.

For context and comparison, note that the U.S. has some 326 million citizens, and China nearly 1.4 billion. China will have spent just over one-fourth of what the U.S. paid for prescription drugs in 2018, with roughly four times the number of health citizens.

The rate of growth of Rx spending looks fairly flat from 2019 to 2023, the second bar chart illustrates, with net growth of spending just over 4% by 2021-2023.

This moderate growth rate is a moment in time, because IQVIA expects a pipeline of new and more expensive products to be launched as older brands continue to come off-patent — the moderating force on the price-driven growth of the new specialty drugs.

The second chart illustrates costs of drugs by type and launch year, showing that the median list price for oncology and orphan drugs (defined as medicines that treat fewer than 200,000 patients globally) could exceed $200,000 per year by 2023. Thus, while the costs of traditional drugs aren’t increasing far above the rate of inflation, the new-new therapies are much higher-priced.

See the dark blue dot in 2023 north of the other dots, representing the median costs for a non-oncology drug with orphan status priced around $300,000.

Other key trends to expect leading to 2023 will be:

The rise of patient advocacy roles in pharma companies

The growing adoption of artificial intelligence and machine learning by pharma companies to drive more efficient drug discovery

More philanthropic organizations targeting neglected tropical and public health diseases

The increased use of real-world evidence (RWE) and patient involvement in clinical trials using consumer-generated technology.

IQVIA rightly calls out digital therapeutics (DTx) in this year’s report, noting the growth of mobile apps and digital tools submitted to the FDA for clearance or approvals. The first FDA cleared DTx was reSET from Pear Therapeutics, cleared in November 2018. This is used for the treatment of substance use disorder and is the first of many conditions Pear is developing in the mode of software-as-medicine to complement the usual standard of care.

DTx companies have been striking partnerships with pharma companies to help them “surround the pill” with service. We can anticipate more of these collaborations going forward as pharmas look to add value beyond the pill, and innovators leverage peoples’ everyday relationships with and trust in consumer technologies.

The limiting factor here will be proving the evidence for DTx on a case-by-case basis. Thus far, the FDA has been welcoming to these concepts.

Health Populi’s Hot Points:  I introduced this post noting today is the first of what will be a long and deep look into prescription drug pricing in America. IQVIA recognizes that, “the (U.S.) Federal government has proposed a sweeping set of pricing reforms for government programs with varying levels of impact and probability of being enacted.” Furthermore, “the next five years likely pose a number of challenges to biopharmaceutical companies, with payer actions on prices looming.”

The last chart was published today in Bloomberg, observing that drug stocks were under-performing ahead of today’s first Congressional hearing on the topic of drug prices.

The Democratic-led House of Representatives may be blamed for this hazing, but in fact voters across political party have been interested in the Federal government taking more assertive and proactive action for prescription drug prices. Polls among voters for several years have found that this issue is a concern for majorities of Democrats, Independents, and Republicans.

In an America lacking consensus across the wide range of issues on voters’ minds, health care costs – and particularly Rx costs and prices – rank top of mind for voters and House Democrats.

Americans have come to learn the role they play in subsidizing the cost of drugs and their development for the world’s health citizens. Note my math on the China ratio of 1:4 dollars spent on prescription drugs versus the U.S., with over four times the number of people.

This topic will inevitably be part of ongoing political debates as we lead up to the 2020 Presidential election. The patient is the consumer is the payor of health care, including prescription drugs at the point of purchase.

The post In 2023, the U.S. Will Still Be the #1 Prescription Drug Spender in the World, IQVIA Forecasts appeared first on HealthPopuli.com.

In 2023, the U.S. Will Still Be the #1 Prescription Drug Spender in the World, IQVIA Forecasts posted first on http://dentistfortworth.blogspot.com

[titheguerrero]

In 2023, the U.S. Will Still Be the #1 Prescription Drug Spender in the World, IQVIA Forecasts

Today, as Congress kicks off hearings about the cost of prescription drugs in the United States, IQVIA published its 2019 report on The Global Use of Medicine in 2019 and Outlook to 2023. The top-line of the research is the robust pharma market growth will be driven by two factors, and limited by two others: spending in the U.S. and emerging markets (coined “pharmerging” by IQVIA) will push up spending, while limiting factors on growth will be increasing generics and expiration of brand patents.

The U.S. will continue to be the number 1 prescription drug spender in the world to 2023, IQVIA forecasts, shown in the first chart where I clipped the top 20 to 10 top spenders. The U.S. will be followed by China, Japan, Germany, and Brazil in 2023.

For context and comparison, note that the U.S. has some 326 million citizens, and China nearly 1.4 billion. China will have spent just over one-fourth of what the U.S. paid for prescription drugs in 2018, with roughly four times the number of health citizens.

The rate of growth of Rx spending looks fairly flat from 2019 to 2023, the second bar chart illustrates, with net growth of spending just over 4% by 2021-2023.

This moderate growth rate is a moment in time, because IQVIA expects a pipeline of new and more expensive products to be launched as older brands continue to come off-patent — the moderating force on the price-driven growth of the new specialty drugs.

The second chart illustrates costs of drugs by type and launch year, showing that the median list price for oncology and orphan drugs (defined as medicines that treat fewer than 200,000 patients globally) could exceed $200,000 per year by 2023. Thus, while the costs of traditional drugs aren’t increasing far above the rate of inflation, the new-new therapies are much higher-priced.

See the dark blue dot in 2023 north of the other dots, representing the median costs for a non-oncology drug with orphan status priced around $300,000.

Other key trends to expect leading to 2023 will be:

The rise of patient advocacy roles in pharma companies

The growing adoption of artificial intelligence and machine learning by pahrma companies to drive more efficient drug discovery

More philanthropic organizations targeting neglected tropical and public health diseases

The increased use of real-world evidence (RWE) and patient involvement in clinical trials using consumer-generated technology.

IQVIA rightly calls out digital therapeutics (DTx) in this year’s report, noting the growth of mobile apps and digital tools submitted to the FDA for clearance or approvals. The first FDA cleared DTx was reSET from Pear Therapeutics, cleared in November 2018. This is used for the treatme

nt of substance use disorder and is the first of many conditions Pear is developing in the mode of software-as-medicine to complement the usual standard of care.

DTx companies have been striking partnerships with pharma companies to help them “surround the pill” with service. We can anticipate more of these collaborations going forward as pharmas look to add value beyond the pill, and innovators leverage peoples’ everyday relationships with and trust in consumer technologies.

The limiting factor here will be proving the evidence for DTx on a case-by-case basis. Thus far, the FDA has been welcoming to these concepts.

Health Populi’s Hot Points:  I introduced this post noting today is the first of what will be a long and deep look into prescription drug pricing in America. IQVIA recognizes that, “the (U.S.) Federal government has proposed a sweeping set of pricing reforms for government programs with varying levels of impact and probability of being enacted.” Furthermore, “the next five years likely pose a number of challenges to biopharmaceutical companies, with payer actions on prices looming.”

The last chart was published today in Bloomberg, observing that drug stocks were under-performing ahead of today’s first Congressional hearing on the topic of drug prices.

The Democratic-led House of Representatives may be blamed for this hazing, but in fact voters across political party have been interested in the Federal government taking more assertive and proactive action for prescription drug prices. Polls among voters for several years have found that this issue is a concern for majorities of Democrats, Independents, and Republicans.

In an America lacking consensus across the wide range of issues on voters’ minds, health care costs – and particularly Rx costs and prices – rank top of mind for voters and House Democrats.

Americans have come to learn the role they play in subsidizing the cost of drugs and their development for the world’s health citizens. Note my math on the China ratio of 1:4 dollars spent on prescription drugs versus the U.S., with over four times the number of people.

This topic will inevitably be part of ongoing political debates as we lead up to the 2020 Presidential election. The patient is the consumer is the payor of health care, including prescription drugs at the point of purchase.

The post In 2023, the U.S. Will Still Be the #1 Prescription Drug Spender in the World, IQVIA Forecasts appeared first on HealthPopuli.com.

Article source:Health Populi

[cancersfakianakis1]

The Concept of Biosimilars: From Characterization to Evolution—A Narrative Review

AbstractBiologic agents are currently the fastest emerging segment of drug expenditure. Unlike chemically synthesized small‐molecule drugs, biologics are more complex, medicinal products produced by a living organism. They have become part of the standard of care in the treatment of a large variety of diseases, such as growth disorders, autoimmune diseases, cancer, cardiovascular illnesses, hemophilia, and rare genetic conditions, to name a few. Biosimilars, which are copies of biologics that are highly similar, were introduced in the market with an aim to offer efficacy that is not clinically different from the originator or reference product, at lower prices. We aim to clarify the concept of biosimilar, from definitions, history, market entry, challenges faced, and future evolution. For that purpose, we performed a literature search on the sites of the medicines regulatory agencies and PubMed from 1990 to 2014 with the keywords “biosimilars,” “market,” and “regulatory.” In 2006, the first biosimilar, somatropin [rDNA origin], was marketed and led the way for biosimilar drug manufacturing. As a result, manufacturers have entered a diversified competition, facing challenges in manufacturing these complex agents, such as immunogenicity and efficiency. Biosimilars are set to evolve differently in various markets, namely the U.S., Japan, the European Union, and the “pharmerging” economies.Implications for Practice.This article highlights the importance of biosimilars, as a cost‐cutting strategy, in the delivery of state‐of‐the‐art health care in developing countries, at a fraction of what a reference biological agent would cost. http://ift.tt/2FHlyyw

[palebearwombat-blog]

Global Pharmerging Market Services, Major Application, Elite Solutions, Top Health Programs 2017

Qyresearchreports include new market research report "Global Pharmerging Market Research Report 2017" to its huge collection of research reports.

A new intelligence study presents a comprehensive overview of the global Pharmerging market, offering insights into the key growth factors and lucrative opportunities. In addition, the key regional segments, product segmentation, and the primary applications have been discussed at length in the scope of the research report. The research report, with a view to offer a clear understanding of the global Pharmerging market, provides a detailed information regarding the key growth factors, current trends, recent developments, and the limitations faced by the prominent players operating in the overall market.

To Get Sample Copy of Report visit @ http://www.qyresearchreports.com/sample/sample.php?rep_id=973660&type=E

The research report has furnished answers to several burning questions concerning the growth and development of the global Pharmerging market. Some of them are given below:

Which product segment is expected to lead in the global Pharmerging market? What is the anticipated growth rate of the global Pharmerging market in the forecast period? Which regional segment is estimated to account for a massive share of the global Pharmerging market? What are the primary driving factors of the global Pharmerging market? What are the vital challenges faced by the prominent players in the global Pharmerging market? Which current trends are likely to offer promising growth prospects in the next few years? How is the competitive landscape of the global Pharmerging market at present?

Furthermore, the study offers a detailed overview of the global Pharmerging market in terms of the competitive scenario. A list of all the leading players operating in the global Pharmerging market has been listed in the study, along with the key strategies that are being used by them in order to flourish and sustain in the market. Additionally, the company profiles, product portfolio, financial overview, SWOT analysis, mergers and acquisitions, and the latest developments have been discussed in the research study to offer a strong understanding of the global Pharmerging market.

Browse Complete Report with TOC @ http://www.qyresearchreports.com/report/global-pharmerging-market-research-report-2017.htm

Table of Contents

Global Pharmerging Market Research Report 2017 1 Pharmerging Market Overview 1.1 Product Overview and Scope of Pharmerging 1.2 Pharmerging Segment by Type 1.2.1 Global Production Market Share of Pharmerging by Type in 2015 1.2.2 Tier 1 1.2.3 Tier 2 1.2.4 Tier 3 1.3 Pharmerging Segment by Application 1.3.1 Pharmerging Consumption Market Share by Application in 2015 1.3.2 Lung Cancer 1.3.3 Breast Cancer 1.3.4 Chronic Myeloid Leukemia 1.3.5 Lymphomas 1.3.6 Other 1.4 Pharmerging Market by Region 1.4.1 North America Status and Prospect (2012-2022) 1.4.2 Europe Status and Prospect (2012-2022) 1.4.3 China Status and Prospect (2012-2022) 1.4.4 Japan Status and Prospect (2012-2022) 1.4.5 Southeast Asia Status and Prospect (2012-2022) 1.4.6 India Status and Prospect (2012-2022) 1.5 Global Market Size (Value) of Pharmerging (2012-2022)

2 Global Pharmerging Market Competition by Manufacturers 2.1 Global Pharmerging Production and Share by Manufacturers (2015 and 2016) 2.2 Global Pharmerging Revenue and Share by Manufacturers (2015 and 2016) 2.3 Global Pharmerging Average Price by Manufacturers (2015 and 2016) 2.4 Manufacturers Pharmerging Manufacturing Base Distribution, Sales Area and Product Type 2.5 Pharmerging Market Competitive Situation and Trends 2.5.1 Pharmerging Market Concentration Rate 2.5.2 Pharmerging Market Share of Top 3 and Top 5 Manufacturers 2.5.3 Mergers & Acquisitions, Expansion

3 Global Pharmerging Production, Revenue (Value) by Region (2012-2017) 3.1 Global Pharmerging Production and Market Share by Region (2012-2017) 3.2 Global Pharmerging Revenue (Value) and Market Share by Region (2012-2017) 3.3 Global Pharmerging Production, Revenue, Price and Gross Margin (2012-2017) 3.4 North America Pharmerging Production, Revenue, Price and Gross Margin (2012-2017) 3.5 Europe Pharmerging Production, Revenue, Price and Gross Margin (2012-2017) 3.6 China Pharmerging Production, Revenue, Price and Gross Margin (2012-2017) 3.7 Japan Pharmerging Production, Revenue, Price and Gross Margin (2012-2017) 3.8 Southeast Asia Pharmerging Production, Revenue, Price and Gross Margin (2012-2017) 3.9 India Pharmerging Production, Revenue, Price and Gross Margin (2012-2017)

4 Global Pharmerging Supply (Production), Consumption, Export, Import by Regions (2012-2017) 4.1 Global Pharmerging Consumption by Regions (2012-2017) 4.2 North America Pharmerging Production, Consumption, Export, Import (2012-2017) 4.3 Europe Pharmerging Production, Consumption, Export, Import (2012-2017) 4.4 China Pharmerging Production, Consumption, Export, Import (2012-2017) 4.5 Japan Pharmerging Production, Consumption, Export, Import (2012-2017) 4.6 Southeast Asia Pharmerging Production, Consumption, Export, Import (2012-2017) 4.7 India Pharmerging Production, Consumption, Export, Import (2012-2017)

5 Global Pharmerging Production, Revenue (Value), Price Trend by Type 5.1 Global Pharmerging Production and Market Share by Type (2012-2017) 5.2 Global Pharmerging Revenue and Market Share by Type (2012-2017) 5.3 Global Pharmerging Price by Type (2012-2017) 5.4 Global Pharmerging Production Growth by Type (2012-2017)

6 Global Pharmerging Market Analysis by Application 6.1 Global Pharmerging Consumption and Market Share by Application (2012-2017) 6.2 Global Pharmerging Consumption Growth Rate by Application (2012-2017) 6.3 Market Drivers and Opportunities 6.3.1 Potential Applications 6.3.2 Emerging Markets/Countries

For Latest QYResearchreports Press Release Visit @ http://www.qyresearchreports.com/press-releases.htm

Contact Us

1820 Avenue M Suite #1047 Brooklyn, NY 11230 United States +1-518-621-2074 866-997-4948 USA-Canada Toll free sales@qyresearchreports.com For Latest Press Release Visit @ http://www.qyresearchreports.com/press-releases.htm Follow us on Linkedin @ http://bit.ly/2c0W5l2

[sandlerresearch]

Global Pharmerging Markets 2017-2021 published on

http://www.sandlerresearch.org/global-pharmerging-markets-2017-2021.html

Global Pharmerging Markets 2017-2021

About Pharmerging The immense growth potential in pharmerging market has driven large multinational pharmaceutical companies to focus on these regions by pursuing organic as well as in-organic routes. To make in-roads into the new geography, the large players usually take in-organic route through strategic expansion initiatives such as acquisitions and alliances. For instance, in December 2015, AstraZeneca entered into a deal with WuXi to acquire its biologics manufacturing facilities in China to expand locally.

The analysts forecast global pharmerging market to grow at a CAGR of 12.88% during the period 2017-2021.

Covered in this report The report covers the present scenario and the growth prospects of the global pharmerging market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of pharmaceutical drugs in pharmerging markets, which are further divided into Tier I, II and III.

The market is divided into the following segments based on geography: Tier 1 Tier 2 Tier 3 The report, Global Pharmerging Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Key vendors AstraZeneca GlaxoSmithKline Pfizer Sanofi Novartis Other prominent vendors Abbott Laboratories AbbVie Alexion Pharmaceuticals Allergan Amgen Aspen Astellas Pharma Baxter Bayer Biogen Boehringer Ingelheim Bristol-Myers Squibb Celgene CSL Behring Daiichi Sankyo Dainippon Sumitomo Pharma Eisai Eli Lilly Endo Health Pharmaceuticals F. Hoffmann-La Roche Fresenius Gilead Grifols H. Lundbeck Hospira Johnson & Johnson Kyowa Hakko Kirin Mallinckrodt Pharmaceuticals Menarini Mitsubishi Tanabe Pharma Mylan Novo Nordisk Otsuka Shire STADA Arzneimittel Sun Pharmaceutical Takeda Pharma Teva Pharmaceutical Industries UCB Valeant Pharmaceuticals Market driver Limitations in developed economies fuels demand in emerging economies For a full, detailed list, view our report Market challenge Stringent price control and generic -centric usage lead to value erosion For a full, detailed list, view our report Market trend Potential of new countries in emerging markets For a full, detailed list, view our report Key questions answered in this report What will the market size be in 2021 and what will the growth rate be? What are the key market trends? What is driving this market? What are the challenges to market growth? Who are the key vendors in this market space? What are the market opportunities and threats faced by the key vendors? What are the strengths and weaknesses of the key vendors?

[marketresearchtrendsblog]

Fabric Conditioners Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2025

The report on the global fabric conditioners market provides qualitative and quantitative analysis for the period from 2017 to 2025. The report predicts the global fabric conditioners market to grow with a CAGR of 4.3% over the forecast period from 2019-2025. The study on fabric conditioners market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2017 to 2025. The report on fabric conditioners market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global fabric conditioners market over the period of 2017 to 2025. Moreover, the report is a collective presentation of primary and secondary research findings.

Request to Fill The Form To get Sample Copy of This Report: https://www.sdki.jp/sample-request-104024 Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global fabric conditioners market over the period of 2017 to 2025. Further, IGR- Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider. Report Findings 1) Drivers • Growing disposable income • Increasing purchasing power of consumers • Aggressive advertising by MNC companies 2) Restraints • Fabric conditioners fragrances can affect on health 3) Opportunities • High demand for eco-friendly fabric conditioners Research Methodology A) Primary Research Our primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached include 1. Key Opinion Leaders associated with Infinium Global Research 2. Internal and External subject matter experts 3. Professionals and participants from the industry Our primary research respondents typically include 1. Executives working with leading companies in the market under review 2. Product/brand/marketing managers 3. CXO level executives 4. Regional/zonal/ country managers 5. Vice President level executives. B) Secondary Research Secondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. At Infinium Global Research, each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources. The secondary sources of the data typically include 1. Company reports and publications 2. Government/institutional publications 3. Trade and associations journals 4. Databases such as WTO, OECD, World Bank, and among others. 5. Websites and publications by research agencies Segment Covered The global fabric conditioners market is segmented on the basis of product type, distribution channel, and applications. The Global Fabric Conditioners Market by Product Type • Liquid Softener • Dryer Sheet • Other Product Types The Global Fabric Conditioners Market by Distribution Channel • Store-based Retailing • Online Retailing The Global Fabric Conditioners Market by Applications • Residential • Commercial Company Profiles The companies covered in the report include • Colgate-Palmolive Co. • Henkel AG & Co. KGaA • Procter & Gamble • Church & Dwight • Kao Corporation • Nakoma Products • Reckitt Benckiser • Unilever PLC • Procter & Gamble Co. • LG Household and Healthcare • Other companies What does this report deliver? 1. Comprehensive analysis of the global as well as regional markets of the fabric conditioners market. 2. Complete coverage of all the segments in the fabric conditioners market to analyze the trends, developments in the global market and forecast of market size up to 2025. 3. Comprehensive analysis of the companies operating in the global fabric conditioners market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company. 4. IGR- Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.

The dynamic nature of business environment in the current global economy is raising the need amongst business professionals to update themselves with current situations in the market. To cater such needs, Shibuya Data Count provides market research reports to various business professionals across different industry verticals, such as healthcare & pharmaceutical, IT & telecom, chemicals and advanced materials, consumer goods & food, energy & power, manufacturing & construction, industrial automation & equipment and agriculture & allied activities amongst others.

Related Links:

water softeners market walnut oil market saffron extract market recycled glass market plastic surgery market pizza market photo printing and merchandise market pharmerging market motorcycle lighting market motorcycle infotainment system market motorcycle adaptive cruise control market lifestyle drugs market isopropyl alcohol market hybrid seeds market

[marketresearchtrendsblog]

Fan-out Wafer Level Packaging Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2025

The report on the global fan-out wafer level packaging market provides qualitative and quantitative analysis for the period from 2017 to 2025. The report predicts the global fan-out wafer level packaging market to grow at a healthy CAGR over the forecast period from 2019-2025. The study on fan-out wafer level packaging market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2017 to 2025. The report on fan-out wafer level packaging market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global fan-out wafer level packaging market over the period of 2017 to 2025. Moreover, the report is a collective presentation of primary and secondary research findings.

Request to Fill The Form To get Sample Copy of This Report: https://www.sdki.jp/sample-request-104025 Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global fan-out wafer level packaging market over the period of 2017 to 2025. Further, IGR- Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider. Report Findings 1) Drivers • Increasing demand for compactly designed electronics across the globe • Developments in wireless communication technologies • Integration of Human-Machine Interface (HMI) technologies 2) Restraints • The high cost of the overall packaging and manufacturing 3) Opportunities • Increasing demand for compactly designed electronics Research Methodology A) Primary Research Our primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached include 1. Key Opinion Leaders associated with Infinium Global Research 2. Internal and External subject matter experts 3. Professionals and participants from the industry Our primary research respondents typically include 1. Executives working with leading companies in the market under review 2. Product/brand/marketing managers 3. CXO level executives 4. Regional/zonal/ country managers 5. Vice President level executives. B) Secondary Research Secondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. At Infinium Global Research, each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources. The secondary sources of the data typically include 1. Company reports and publications 2. Government/institutional publications 3. Trade and associations journals 4. Databases such as WTO, OECD, World Bank, and among others. 5. Websites and publications by research agencies Segment Covered The global fan-out wafer level packaging market is segmented on the basis of technology. The Global Fan-out Wafer Level Packaging Market by Technology • High-density FOWLP • Standard Density FOWLP Company Profiles The companies covered in the report include • Infineon Technologies AG • Amkor Technology • ASE Technology Holding • SAMSUNG ELECTRO-MECHANICS • STATS ChipPAC • Deca Technologies, Inc. • Taiwan Semiconductor Manufacturing Company • Nanium S.A • ADL Engineering Ltd • Fujikura Ltd. • Other companies What does this report deliver? 1. Comprehensive analysis of the global as well as regional markets of the fan-out wafer level packaging market. 2. Complete coverage of all the segments in the fan-out wafer level packaging market to analyze the trends, developments in the global market and forecast of market size up to 2025. 3. Comprehensive analysis of the companies operating in the global fan-out wafer level packaging market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company. 4. IGR- Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.

The dynamic nature of business environment in the current global economy is raising the need amongst business professionals to update themselves with current situations in the market. To cater such needs, Shibuya Data Count provides market research reports to various business professionals across different industry verticals, such as healthcare & pharmaceutical, IT & telecom, chemicals and advanced materials, consumer goods & food, energy & power, manufacturing & construction, industrial automation & equipment and agriculture & allied activities amongst others.

Related Links:

water softeners market walnut oil market saffron extract market recycled glass market plastic surgery market pizza market photo printing and merchandise market pharmerging market motorcycle lighting market motorcycle infotainment system market motorcycle adaptive cruise control market lifestyle drugs market isopropyl alcohol market hybrid seeds market

[realselfblog]

In 2023, the U.S. Will Still Be the #1 Prescription Drug Spender in the World, IQVIA Forecasts

Today, as Congress kicks off hearings about the cost of prescription drugs in the United States, IQVIA published its 2019 report on The Global Use of Medicine in 2019 and Outlook to 2023. The top-line of the research is the robust pharma market growth will be driven by two factors, and limited by two others: spending in the U.S. and emerging markets (coined “pharmerging” by IQVIA) will push up spending, while limiting factors on growth will be increasing generics and expiration of brand patents.

The U.S. will continue to be the number 1 prescription drug spender in the world to 2023, IQVIA forecasts, shown in the first chart where I clipped the top 20 to 10 top spenders. The U.S. will be followed by China, Japan, Germany, and Brazil in 2023.

For context and comparison, note that the U.S. has some 326 million citizens, and China nearly 1.4 billion. China will have spent just over one-fourth of what the U.S. paid for prescription drugs in 2018, with roughly four times the number of health citizens.

The rate of growth of Rx spending looks fairly flat from 2019 to 2023, the second bar chart illustrates, with net growth of spending just over 4% by 2021-2023.

This moderate growth rate is a moment in time, because IQVIA expects a pipeline of new and more expensive products to be launched as older brands continue to come off-patent — the moderating force on the price-driven growth of the new specialty drugs.

The second chart illustrates costs of drugs by type and launch year, showing that the median list price for oncology and orphan drugs (defined as medicines that treat fewer than 200,000 patients globally) could exceed $200,000 per year by 2023. Thus, while the costs of traditional drugs aren’t increasing far above the rate of inflation, the new-new therapies are much higher-priced.

See the dark blue dot in 2023 north of the other dots, representing the median costs for a non-oncology drug with orphan status priced around $300,000.

Other key trends to expect leading to 2023 will be:

The rise of patient advocacy roles in pharma companies

The growing adoption of artificial intelligence and machine learning by pharma companies to drive more efficient drug discovery

More philanthropic organizations targeting neglected tropical and public health diseases

The increased use of real-world evidence (RWE) and patient involvement in clinical trials using consumer-generated technology.

IQVIA rightly calls out digital therapeutics (DTx) in this year’s report, noting the growth of mobile apps and digital tools submitted to the FDA for clearance or approvals. The first FDA cleared DTx was reSET from Pear Therapeutics, cleared in November 2018. This is used for the treatment of substance use disorder and is the first of many conditions Pear is developing in the mode of software-as-medicine to complement the usual standard of care.

DTx companies have been striking partnerships with pharma companies to help them “surround the pill” with service. We can anticipate more of these collaborations going forward as pharmas look to add value beyond the pill, and innovators leverage peoples’ everyday relationships with and trust in consumer technologies.

The limiting factor here will be proving the evidence for DTx on a case-by-case basis. Thus far, the FDA has been welcoming to these concepts.

Health Populi’s Hot Points:  I introduced this post noting today is the first of what will be a long and deep look into prescription drug pricing in America. IQVIA recognizes that, “the (U.S.) Federal government has proposed a sweeping set of pricing reforms for government programs with varying levels of impact and probability of being enacted.” Furthermore, “the next five years likely pose a number of challenges to biopharmaceutical companies, with payer actions on prices looming.”

The last chart was published today in Bloomberg, observing that drug stocks were under-performing ahead of today’s first Congressional hearing on the topic of drug prices.

The Democratic-led House of Representatives may be blamed for this hazing, but in fact voters across political party have been interested in the Federal government taking more assertive and proactive action for prescription drug prices. Polls among voters for several years have found that this issue is a concern for majorities of Democrats, Independents, and Republicans.

In an America lacking consensus across the wide range of issues on voters’ minds, health care costs – and particularly Rx costs and prices – rank top of mind for voters and House Democrats.

Americans have come to learn the role they play in subsidizing the cost of drugs and their development for the world’s health citizens. Note my math on the China ratio of 1:4 dollars spent on prescription drugs versus the U.S., with over four times the number of people.

This topic will inevitably be part of ongoing political debates as we lead up to the 2020 Presidential election. The patient is the consumer is the payor of health care, including prescription drugs at the point of purchase.

The post In 2023, the U.S. Will Still Be the #1 Prescription Drug Spender in the World, IQVIA Forecasts appeared first on HealthPopuli.com.

In 2023, the U.S. Will Still Be the #1 Prescription Drug Spender in the World, IQVIA Forecasts posted first on http://dentistfortworth.blogspot.com

[realselfblog]

In 2023, the U.S. Will Still Be the #1 Prescription Drug Spender in the World, IQVIA Forecasts

Today, as Congress kicks off hearings about the cost of prescription drugs in the United States, IQVIA published its 2019 report on The Global Use of Medicine in 2019 and Outlook to 2023. The top-line of the research is the robust pharma market growth will be driven by two factors, and limited by two others: spending in the U.S. and emerging markets (coined “pharmerging” by IQVIA) will push up spending, while limiting factors on growth will be increasing generics and expiration of brand patents.

The U.S. will continue to be the number 1 prescription drug spender in the world to 2023, IQVIA forecasts, shown in the first chart where I clipped the top 20 to 10 top spenders. The U.S. will be followed by China, Japan, Germany, and Brazil in 2023.

For context and comparison, note that the U.S. has some 326 million citizens, and China nearly 1.4 billion. China will have spent just over one-fourth of what the U.S. paid for prescription drugs in 2018, with roughly four times the number of health citizens.

The rate of growth of Rx spending looks fairly flat from 2019 to 2023, the second bar chart illustrates, with net growth of spending just over 4% by 2021-2023.

This moderate growth rate is a moment in time, because IQVIA expects a pipeline of new and more expensive products to be launched as older brands continue to come off-patent — the moderating force on the price-driven growth of the new specialty drugs.

The second chart illustrates costs of drugs by type and launch year, showing that the median list price for oncology and orphan drugs (defined as medicines that treat fewer than 200,000 patients globally) could exceed $200,000 per year by 2023. Thus, while the costs of traditional drugs aren’t increasing far above the rate of inflation, the new-new therapies are much higher-priced.

See the dark blue dot in 2023 north of the other dots, representing the median costs for a non-oncology drug with orphan status priced around $300,000.

Other key trends to expect leading to 2023 will be:

The rise of patient advocacy roles in pharma companies

The growing adoption of artificial intelligence and machine learning by pharma companies to drive more efficient drug discovery

More philanthropic organizations targeting neglected tropical and public health diseases

The increased use of real-world evidence (RWE) and patient involvement in clinical trials using consumer-generated technology.

IQVIA rightly calls out digital therapeutics (DTx) in this year’s report, noting the growth of mobile apps and digital tools submitted to the FDA for clearance or approvals. The first FDA cleared DTx was reSET from Pear Therapeutics, cleared in November 2018. This is used for the treatment of substance use disorder and is the first of many conditions Pear is developing in the mode of software-as-medicine to complement the usual standard of care.

DTx companies have been striking partnerships with pharma companies to help them “surround the pill” with service. We can anticipate more of these collaborations going forward as pharmas look to add value beyond the pill, and innovators leverage peoples’ everyday relationships with and trust in consumer technologies.

The limiting factor here will be proving the evidence for DTx on a case-by-case basis. Thus far, the FDA has been welcoming to these concepts.

Health Populi’s Hot Points:  I introduced this post noting today is the first of what will be a long and deep look into prescription drug pricing in America. IQVIA recognizes that, “the (U.S.) Federal government has proposed a sweeping set of pricing reforms for government programs with varying levels of impact and probability of being enacted.” Furthermore, “the next five years likely pose a number of challenges to biopharmaceutical companies, with payer actions on prices looming.”

The last chart was published today in Bloomberg, observing that drug stocks were under-performing ahead of today’s first Congressional hearing on the topic of drug prices.

The Democratic-led House of Representatives may be blamed for this hazing, but in fact voters across political party have been interested in the Federal government taking more assertive and proactive action for prescription drug prices. Polls among voters for several years have found that this issue is a concern for majorities of Democrats, Independents, and Republicans.

In an America lacking consensus across the wide range of issues on voters’ minds, health care costs – and particularly Rx costs and prices – rank top of mind for voters and House Democrats.

Americans have come to learn the role they play in subsidizing the cost of drugs and their development for the world’s health citizens. Note my math on the China ratio of 1:4 dollars spent on prescription drugs versus the U.S., with over four times the number of people.

This topic will inevitably be part of ongoing political debates as we lead up to the 2020 Presidential election. The patient is the consumer is the payor of health care, including prescription drugs at the point of purchase.

The post In 2023, the U.S. Will Still Be the #1 Prescription Drug Spender in the World, IQVIA Forecasts appeared first on HealthPopuli.com.

In 2023, the U.S. Will Still Be the #1 Prescription Drug Spender in the World, IQVIA Forecasts posted first on http://dentistfortworth.blogspot.com